Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: A systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 59, Issue 10, 2014, Pages 1495-1502

  Liu, Huixin ^a   Ma, Ye ^a   Su, Yingying ^a   Smith, M Kumi ^d   Liu, Ying ^b   Jin, Yantao ^a   Gu, Hongqiu ^c   Wu, Jing ^a   Zhu, Lin ^a   Wang, Ning ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c State Key Laboratory of Cardiovascular Disease Department of Pathology National Center for Cardiovascular Disease   (China)

^d IL   (United States)

Author keywords

Drug resistance; Highly active antiretroviral therapy; HIV AIDS; Meta analysis

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CHINESE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; META ANALYSIS; MULTICENTER STUDY (TOPIC); PLASMA TRANSFUSION; RURAL POPULATION; SEXUAL TRANSMISSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREND STUDY; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PREVALENCE; TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE;

EID: 84918840640     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu590     Document Type: Article

References (48)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999;160:659-65.
3. Thaker HK, Snow MH. HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J 2003;79:36-42.
4. Kaufmann GR, Zaunders J, Cooper DA. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect 1999;75:218-24.
5. De Gruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000;5:41-8.
6. Haubrich R, Demeter L. International perspectives on antiretroviral resistance: clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001;26(suppl 1):S51-9.
7. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350:1023-35.
8. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:e356.
9. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004;18:1539-48.
10. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008;47:712-22.
11. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009;151:241-51.
12. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008;47:825-33.
13. Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011;11:516-24.
14. Zhang F, Haberer JE, Wang Y, et al. National free HIV antiretroviral treatment handbook. 2nd ed. Beijing, China: People's Medical Publishing House, 2008.
15. Zhao D, Wen Y, Ma Y, et al. Expansion of China's free antiretroviral treatment program. Chin Med J (Engl) 2012;125:3514-21.
16. Ma Y, Zhao D, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis. 2010;50:264-71.
17. Zhang Y, Zhou Z, Xing H, et al. The antiviral therapy efficiency and drug resistance analysis among 140 HIV/AIDS patients in Yunnan. Soft Sci Health 2012;26:38-41.
18. Li H, Guo L, Li H, et al. Occurrence of human immunodeficiency virus-1 resistance through a six-year surveillance in rural areas of Henan. Natl Med J China 2011;91:1443-7.
19. Liu T, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006;42:1608-18.
20. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I (2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008;8:79.
21. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. Available at: http://www.R-project.org/. Accessed 23 March 2014.
22. Wang Y, Xing H, Wang Z, et al. Study on influencing factors of emergence of HIV drug resistance in one county of Henan province. Chinese J Public Health 2007;23:803-5.
23. Huang J. The characteristic of drug resistance in AIDS patients who were former plasma donors and receiving free antiretroviral therapy in China [dissertation]. Wuhan, China: Wuhan Institute of Virology, Chinese Academy of Science, 2008.
24. Li T, Dai Y, Kuang J, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One 2008;3:e3918.
25. Zhang M, Han X, Hu Q, et al. Cohort study of highly active antiretroviral therapy and drug resistant mutation in Henan Province, China. Clin J Lab Med 2008;31:1101-5.
26. Ruan Y, Xing H, Wang X, et al. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop Med Int Health 2010;15:1357-63.
27. Chen X, Tang X, Cai W, et al. The therapeutic effects of highly active anti-retroviral therapy in 74 treatment-naive patients with AIDS in China. Chinese J Int Med 2011;50:59-62.
28. Cao X, Yuan Y, Liu H, et al. Study on highly active antiretroviral therapy and drug resistance mutation in Henan Province. Henan Yu Fang Yi Xue Za Zhi 2011;22:11-2.
29. Wang X, Yang L, Li H, et al. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011;9:103-11.
30. Wang L. Efficacy and predictive factors of virologic and immunologic outcome of a 48-week cART in 517 Chinese treatment-naive HIV/AIDS patients [dissertation]. Beijing, China: Department of Infectious Disease, Peking Union Medical College Hospital, 2012.
31. Liao L, Xing H, Su B, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS 2013;27:1815-24.
32. Wang J, He C, Hsi JH, et al. Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012. PLoS One 2014;9:e88305.
33. Zhang M, Han X, Cui W, et al. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis 2008;61:361-5.
34. Yao S. Antiretroviral treatment effect of 735 AIDS patients from Dehong prefecture. Presented at: Fourth national Conference on Immune Diagnosis and Vaccines; 2009; Guiyang, China.
35. Yuan Y, Xing H, Wang X, et al. The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province. Chinese J Prev Med 2011;45:619-24.
36. Zheng J, Chen L, Zhang J, et al. Drug resistance in 274 HIV/AIDS case receiving HAART in Zhejiang province and related risk factors. Chinese J AIDS STD 2011;17:519-22.
37. Zheng B. The drug resistance and its factors among HIV-infected patients who accepted HAART in Henan Province, China [dissertation]. Beijing, China: State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, 2011.
38. Cui W, Liu J, Xue X, et al. Cross-sectional analysis on drug resistance profile of acquired immune deficiency syndrome patients receiving a long-term antiretroviral treatment in Henan. Chinese J Exp Clin Virol 2012;26:168-71.
39. Qin B, He J, Zou X, et al. Analysis of curative effect and drug-resistance during anti-retroviral treatment in 252 HIV/AIDS patients in Hunan. Pract Prev Med 2012;19:964-7.
40. Sun X, Lin B, Su S, et al. Mutation of drug resistant gene in HIV/AIDS patients with antiretroviral therapy in Shandong province in 2011. Chinese J Prev Med 2012;46:982-6.
41. Xiao Z, Guo H, Xuan X, et al. Genotypic drug resistance and risk factors among antiretroviral treatment patients in Jiangsu province. ACTA Universitatis Medicinalis Nanjing (Natural Science) 2012;32:16-9.
42. Yuan Y, Wang Z, Shao Y, et al. Study on prevalence of HIV-1 drug resistance in AIDS former blood donors receiving to HAART in Henan province. Modern Prev Med 2012;39:5954-6.
43. Cui W, Xue X, Liu J, et al. A cross-sectional study on the prevalence of HIV drug resistance in patients receiving antiretroviral treatment in Shenqiu county, Henan province. Chinese J Epidemiol 2013;34:218-20.
44. Zhao D, Ma Y, Zhang F, et al. Drug resistance among HIV-infected adults receiving long term first-line antiretroviral treatment in China. Chinese J Exp Clin Infect 2013;7:204-9.
45. Xing H, Ruan Y, Li J, et al. HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients. PLoS One 2013;8:e54917.
46. Ministry of Health of the People's Republic of China, UNAIDS, WHO. Estimation on epidemic situation of HIV/AIDS in China in 2011. 2011.
47. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
48. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001;7:1016-20.